AAA March 2015 – Page 16

Pfizer backs $35m Mersana round

US-based pharmaceutical company Mersana Therapeutics secured $35m yesterday in a series B-1 round featuring pharmaceutical company Pfizer’s corporate venturing arm Pfizer Venture Investments. New Enterprise Associates led the round, which also included fund manager Fidelity Worldwide Investments’ pharmaceutical investment arm Fidelity Biosciences, Rock Springs Capital Management and Elliott Sigal, former head of research and development… Continue reading Pfizer backs $35m Mersana round